featured
-
A Guest Perspective for Gratitude Day: Why Huntington’s Disease May Be Neuroscience’s Best Investment
⏱️ 6 min read | Today, on Gratitude Day, we share a guest piece from HD researcher Roy Maimon that Huntington’s disease is neuroscience’s best investment, not just for its scientific clarity, but for the remarkable community built around it.
By Roy Maimon -
The Girl at the End of the World: A Gratitude Day Reflection on the Place that Built Our Science
⏱️ 9 min read | This Gratitude Day, March 23rd, we celebrate the extraordinary partnership between HD families, scientists, and caregivers, and reflect on the place that built the science on which we all stand.
-
Turning down mismatch repair genes slows Huntington’s repeat growth in human neurons
⏱️ 10 min read | In a human cellular system, scientists dialed back mismatch repair genes to reduce CAG expansion by up to 69%. This work is in its early days, but it shows promise for “anti-expansion” therapies that could be used to delay HD onset.
-
Huntington’s Disease Therapeutics Conference 2026 – Day 3
⏱️ 29 min read | Day 3 of the HD Therapeutics Conference dives into breakthrough science, new tools and bold ideas that are pushing HD research toward better treatments.
-
Huntington’s Disease Therapeutics Conference 2026 – Day 2
⏱️ 18 min read | HDBuzz is back with Day 2 of the 21st annual CHDI HD Therapeutics Conference in Palm Springs, CA. We heard about new techniques to zoom in on HD biology in extraordinary detail.
-
Huntington’s Disease Therapeutics Conference 2026 – Day 1
⏱️ 33 min read | HDBuzz is at CHDI’s Huntington’s Disease Therapeutics Conference, ready to bring you live updates from the most recent research in the field. Get ready for some exciting science!
-
Australia Opens The Door for SKY-0515: Skyhawk Seeks Provisional Approval for Its Oral HD Drug
⏱️ 8 min read | An oral Huntington’s disease drug is eligible for accelerated approval in Australia. This isn’t full approval yet, but it opens a faster path to potentially getting this once-daily pill to people with HD sooner.
-
The road ahead for uniQure: FDA says more data needed for AMT-130 gene therapy
⏱️ 10 min read | The FDA wants more data before approving AMT-130 for Huntington’s disease in the U.S. On March 2026, uniQure shared in an update that current Phase 1/2 data weren’t enough for the agency. A new randomized, sham-controlled trial may be required.
-
Vico’s Trial Adjusts With Twice-Yearly Dosing, And The U.S. Is Next
⏱️ 6 min read | Vico Therapeutics’ Huntington’s disease drug VO659 is now being tested just twice a year, and the FDA has cleared the way for US trials to begin later this year.
-
February 2026: This Month in Huntington’s Disease Research
⏱️ 8 min read | February 2026 HD research recap: published trial data from branaplam trial; new insights into the genetics of the HD “grey zone”; plus worms, brain circuits, eye tracking, and the hidden psychological weight of living at risk.